133P Neoadjuvant pembrolizumab plus lenvatinib in resectable stage III melanoma patients (pts) (NeoPele): Analysis of the peripheral immune profile correlated to pathological response

I. Pires da Silva; Jordan W. Conway; Linda Smith; Anand Ramanathan; Nurudeen A. Adegoke; R. Rawson; P. Grover; Nigel Maher; Jorja Braden; M. Gonzalez; Umaimainthan Palendira; A.M. Menzies; Richard A Scolyer; G.V. Long

doi:10.1016/j.annonc.2024.08.141

Article2024

Neoadjuvant pembrolizumab plus lenvatinib in patients with resectable stage III melanoma (NeoPele): Analysis of tumor microenvironment (TME) correlated to pathological response.

Ines Esteves Domingues Pires Da Silva, Jordan W. Conway, Akshaya Ramanathan, Laura Smith, Robert V. Rawson, Piyush Grover, Nigel Maher, Jorja Braden, Maria Gonzalez, Umaimainthan Palendira, Alexander M. Menzies, Richard A Scolyer, Georgina V. Long

Article2020

A phase II study of neoadjuvant pembrolizumab and lenvatinib for resectable stage III melanoma: The neopele study.

Maria Gonzalez, Alexander M. Menzies, Thomas E. Pennington, Robyn P.M. Saw, Andrew J. Spillane, Jonathan R. Stretch, Kerwin F. Shannon, Sydney Ch’ng, Omgo E. Nieweg, Maria Cruzado Rojas, Monica Osorio, Robert V. Rawson, Peter M. Ferguson, Helen Rizos, Serigne Lo, Richard A Scolyer, Georgina V. Long

Article2022

793P NeoPeLe: A phase II trial of neoadjuvant (NAT) pembrolizumab (Pembro) combined with lenvatinib (Lenva) in resectable stage III melanoma

Georgina V. Long, Andrew J. Spillane, Thomas E. Pennington, Kerwin F. Shannon, Jonathan R. Stretch, Maria Gonzalez, R.P.M. Saw, Serigne Lo, Richard A Scolyer, Alexander M. Menzies

Article2025

Distinct effect of neoadjuvant PD1 alone, PD1+IPI, and PD1+lenvatinib in the peripheral immune profile of melanoma patients (pts) and correlation with pathological (path) response.

Inês Pires da Silva, Jordan W. Conway, Akshaya Ramanathan, Laura Smith, Nurudeen A. Adegoke, Jorja Braden, Maria Gonzalez, Richard A Scolyer, Umaimainthan Palendira, Matteo S. Carlino, Christian U. Blank, Alexander M. Menzies, Georgina V. Long

Article2024

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma

Christian U Blank, Minke W Lucas, Richard A Scolyer, Bart A van de Wiel, Alexander M Menzies, Marta Lopez-Yurda, Lotte L Hoeijmakers, Robyn P M Saw, Judith M Lijnsvelt, Nigel G Maher, Saskia M Pulleman, Maria Gonzalez, Alejandro Torres Acosta, Winan J. van Houdt, Serigne N Lo, Anke M J Kuijpers, Andrew Spillane, W Martin C Klop, Thomas E Pennington, Charlotte L Zuur, Kerwin F Shannon, Beatrijs A Seinstra, Robert V Rawson, John B A G Haanen,

133P Neoadjuvant pembrolizumab plus lenvatinib in resectable stage III melanoma patients (pts) (NeoPele): Analysis of the peripheral immune profile correlated to pathological response

Discussion(0)

Related publications

Neoadjuvant pembrolizumab plus lenvatinib in patients with resectable stage III melanoma (NeoPele): Analysis of tumor microenvironment (TME) correlated to pathological response.

A phase II study of neoadjuvant pembrolizumab and lenvatinib for resectable stage III melanoma: The neopele study.

793P NeoPeLe: A phase II trial of neoadjuvant (NAT) pembrolizumab (Pembro) combined with lenvatinib (Lenva) in resectable stage III melanoma

Distinct effect of neoadjuvant PD1 alone, PD1+IPI, and PD1+lenvatinib in the peripheral immune profile of melanoma patients (pts) and correlation with pathological (path) response.

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma